ALK-positive anaplastic large cell lymphoma (ALCL) represents a subset of non-Hodgkin’s lymphoma that is treated with crizotinib, a dual ALK/MET inhibitor. Despite the remarkable initial response, ALCLs eventually develop resistance to crizotinib. ALK inhibitor resistance in tumors is a complex and heterogeneous process with multiple underlying mechanisms, including ALK gene amplification, ALK kinase domain mutation, and the activation of various bypass signaling pathways. To overcome resistance, multiple promising next-generation ALK kinase inhibitors and rational combinatorial strategies are being developed. To determine how cancers acquire resistance to ALK inhibitors, we established a model of acquired crizotinib resistance by exposing a highly sensitive NPM-ALK-positive ALCL cell line to increasing doses of crizotinib until resistance emerged. We found that the NPM-ALK mutation was selected under intermediate-concentration drug stress in resistant clones, accompanied by activation of the IGF-1R pathway. In the crizotinib-resistant ALCL cell model, the IGF-1R pathway was activated, and combined ALK/IGF-1R inhibition improved therapeutic efficacy. Furthermore, we also detected the NPM-ALK G1269A mutation, which had previously been demonstrated to result in decreased affinity for crizotinib, in the resistant cell model. Although crizotinib was ineffective against cells harboring the NPM-ALK G1269A mutation, five structurally different ALK inhibitors, alectinib, ceritinib, TAE684, ASP3026 and AP26113, maintained activity against the resistant cells. Thus, we have shown that second-generation ALK tyrosine kinase inhibitors or IGF-1R inhibitors are effective in treating crizotinib-resistant tumors.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, AT L (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151):1281–1284
Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566
Duijkers FA, Gaal J, Meijerink JP et al (2012) High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol 180(3):1223–1231
Duyster J, Bai RY, SW M (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20(40):5623–5637
Turner SD, Alexander DR (2005) What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 19(7):1128–1134
Ma Z, Hill DA, Collins MH et al (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosom Cancer 37(1):98–105
Bischof D, Pulford K, Mason DY, SW M (1997) Role of the Nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17(4):2312–2325
Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68(13):4971–4976
Murugan AK, Xing M (2011) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71(13):4403–4411
Antonella B, Elena L, Ludovica R et al (2011) Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 47(1):R11–R23
Mossé YP, Lim MS, Voss SD et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's oncology group phase 1 consortium study. Lancet Oncol 14(6):472–480
Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012
Camidge DR, Bang Y-J, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019
Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12 Pt 1):3314–3322
Qi X, Ma W, Li S, Zhou C (2014) Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer. Lung Cancer 85(2):335–336
Perez CA, Velez M, Raez LE, Santos ES (2014) Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung Cancer 84(2):110–115
Katayama R, Khan TM, Benes C et al (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108(18):7535–7540
Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung Cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734–1739
Guerin A, Sasane M, Zhang J et al (2015) ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiol 39(3):307–312
Gainor JF, Varghese AM, Ou SH et al (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19(15):4273–4281
Doebele RC, Pilling AB, Aisner DL et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5):1472–1482
Isozaki H, Takigawa N, Kiura K (2015) Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers 7(2):763–783
Sasaki T, Koivunen J, Ogino A et al (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71(18):6051–6060
Toyokawa G, Hirai F, Inamasu E et al (2014) Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol 9(12):e86–e87
Friboulet L, Li N, Katayama R et al (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4(6):662–673
Alshareef A, Zhang HF, Huang YH et al (2016) The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers. Sci Rep 6:33710
George SK, Vishwamitra D, Manshouri R, Shi P, Amin HM (2014) The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 5(14):5750–5763
Sakamoto H, Tsukaguchi T, Hiroshima S et al (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19(5):679–690
Galkin AV, Melnick JS, Kim S et al (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104(1):270–275
Ceccon M, Mologni L, Giudici G et al (2015) Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol Cancer Res 13(4):775–783
Zdzalik D, Dymek B, Grygielewicz P et al (2014) Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol 140(4):589–598
Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L (2015) Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med 4(7):953–965
Lovisa F, Cozza G, Cristiani A et al (2015) ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. PLoS One 10(4):e0121378
Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C (2013) Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res 11(2):122–132
Mologni L, Ceccon M, Pirola A et al (2015) NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget 6(8):5720–5734
Amin AD, Li L, Rajan SS et al (2016) TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget 7(17):23715–23729
Tanizaki J, Okamoto I, Okabe T et al (2012) Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 18(22):6219–6226
Ji C, Zhang L, Cheng Y et al (2014) Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 15(5):570–577
Miyawaki M, Yasuda H, Tani T et al (2017) Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer. Mol Cancer Res 15(1):106–114
Cuyas E, Perez-Sanchez A, Micol V, Menendez JA, Bosch-Barrera J (2016) STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle 15(24):3413–3418
Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH (2000) Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 275(20):15099–15105
Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, BA H (1999) Mechanism of protein kinase B activation by insulin/insulin-like growth Factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase—significance for diabetes and Cancer. Pharmacol Ther 82(2–3):409–425
Criswell T, Beman M, Araki S et al (2005) Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280(14):14212–14221
Shi P, Lai R, Lin Q et al (2009) IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood 114(2):360–370
Lovly CM, McDonald NT, Chen H et al (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer. Nat Med 20(9):1027–1034
Wilson C, Nimick M, Nehoff H, Ashton JC (2017) ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. Sci Rep 7(1):13955
Li L, Wang Y, Peng T (2016) Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget 7(23):34442–34452
Zhang J, Wang P, Wu F et al (2012) Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal 24(4):852–858
This study was supported by the National Natural Science Foundation of China (No. 81372532), and the Science and Technology Planning Project of Liaoning Province of China (No. 201800449), and the scientific research foundation for the introduction of talents, Liaoning Cancer Hospital & Institute (No. Z1702). The authors report no conflicts of interest in this work.
Conflict of interests
The authors have declared that no competing interest exists.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study, formal consent is not required.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, Y., Wang, K., Song, N. et al. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. Invest New Drugs 38, 599–609 (2020). https://doi.org/10.1007/s10637-019-00802-7
- Drug resistance